Bromonordiazepam 2.5 mg Pellets

PRODUCT DESCRIPTION

Introduction

Bromonordiazepam, also known as desalkylgidazepam or BNZ, is an active metabolite of the benzodiazepine gidazepam. It exhibits anxiolytic and sedative properties with a relatively long half-life, making it a compound of interest for pharmacological and forensic research. Bromonordiazepam 2.5 mg pellets offer a precise dosing format for research into benzodiazepine receptor mechanisms, anxiolytic effects, and metabolism.

Chemical Properties and Specifications

2.1 Structural and Molecular Characteristics

• Chemical Formula: C15H10BrN2O

• Molecular Weight: 318.15 g/mol

• CAS Number: 2894-61-3

• IUPAC Name: 7-Bromo-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one

• Synonyms:

  • Bromonordiazepam

  • Desalkylgidazepam

  • BNZ

2.2 Physical Properties and Purity Standards

• Appearance: White crystalline pellets

• Dosage Strength: 2.5 mg per pellet

• Purity: Typically ≥98% pharmaceutical grade

• Solubility: Soluble in dimethylformamide (5 mg/mL), dimethyl sulfoxide (5 mg/mL), slightly soluble in ethanol, low solubility in phosphate-buffered saline (0.12 mg/mL, pH 7.2)

• Melting Point: Approximately 220-221°C

• Storage Recommendations: Store in a cool, dry place (-20°C preferred), protected from light and humidity

Pharmacological Profile and Mechanism of Action

3.1 Mechanism of Action

Bromonordiazepam acts as a positive allosteric modulator of the GABA-A receptor complex, enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) activity in the brain. This results in anxiolytic and sedative effects, similar to other benzodiazepines but with extended duration due to its long half-life.

3.2 Research Applications

Used in neuropharmacology research for studying benzodiazepine metabolism, receptor affinity, anxiolytic activity, and pharmacokinetics. The 2.5 mg pellet form allows dose titration and behavioral pharmacology assessments.

Comparative Analysis with Related Compounds

4.1 Compared to Other Benzodiazepines

Bromonordiazepam is related structurally and functionally to diazepam and other classical benzodiazepines but has distinct metabolic pathways and potency profiles. Its long half-life distinguishes it from shorter-acting benzodiazepines.

4.2 Advantages for Research

Consistent purity and pellet form enable precise dosing and reproducibility. It serves as an important compound for studies involving benzodiazepine pharmacology and forensic identification.

Safety and Handling Guidelines

5.1 Laboratory Safety

Use appropriate PPE, including gloves and eye protection. Work in ventilated areas to avoid inhalation. Handle pellets carefully to avoid contamination.

5.2 Disposal

Follow hazardous chemical waste disposal guidelines to prevent environmental harm.

5.3 Regulatory Status

Bromonordiazepam is regulated or controlled in several jurisdictions due to its benzodiazepine classification. Confirm legal status before procurement and research use.

Frequently Asked Questions (FAQs)

1. What is bromonordiazepam?
   Active metabolite of the benzodiazepine gidazepam with anxiolytic properties.

2. What is the dosage strength of the pellets?
   2.5 mg per pellet.

3. What are its primary effects?
   Anxiolytic and sedative effects via GABA-A receptor modulation.

4. How soluble is bromonordiazepam?
   Soluble in DMF and DMSO (~5 mg/mL), slightly soluble in ethanol.

5. Is bromonordiazepam controlled?
   Yes, regulated in many countries.

Conclusion

Bromonordiazepam 2.5 mg pellets provide a reliable, high-purity benzodiazepine metabolite format for advanced neurological and pharmacokinetic research. Their stable dosing and physicochemical profile make them well-suited for neuropharmacological and behavioral studies under regulated conditions.